Pharma Mar SA ( (ES:PHM) ) has shared an announcement.
PharmaMar SA reported an 11% increase in total revenue for 2024, reaching 174.9 million euros, driven by a significant rise in royalties and license agreements. Despite a slight decline in oncology sales, the company achieved a net profit of 26.1 million euros, highlighting its strong financial performance and strategic partnerships, which have bolstered its market position.
More about Pharma Mar SA
PharmaMar SA is a biopharmaceutical company focused on the development and commercialization of marine-derived drugs for oncology treatment. The company is known for its innovative cancer therapies, including Yondelis® and lurbinectedin, and collaborates with partners like Jazz Pharmaceuticals and Janssen.
YTD Price Performance: 24.27%
Average Trading Volume: 1,486
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.82B
For a thorough assessment of PHM stock, go to TipRanks’ Stock Analysis page.